Biomarkers for osteoarthritis: Current status and future prospects

Mobasheri, Ali; Thudium, Christian S.; Bay-Jensen, Anne-Christine; Maleitzke, Tazio; Geissler, Sven; Duda, Georg N.; Winkler, Tobias

doi:10.1016/j.berh.2023.101852

Cited by 7 publications

(4 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This erosion of joint cartilage leads to subchondral bone damage, increased pain sensitivity, and synovial inflammation. In the context of OA, a disability that currently is without treatment options, intricate challenges arise due to the presence of diverse patient subgroups and multifaceted disease etiologies . Additionally, obstacles in delivering drugs to OA patients include the rapid clearance of therapeutic agents from joint spaces and the difficulty in penetrating dense cartilage tissue.…”

Section: Advanced Models To Explore Personalized Nanomedicinesmentioning

confidence: 99%

“…In the context of OA, a disability that currently is without treatment options, 54 intricate challenges arise due to the presence of diverse patient subgroups and multifaceted disease etiologies. 55 Additionally, obstacles in delivering drugs to OA patients include the rapid clearance of therapeutic agents from joint spaces and the difficulty in penetrating dense cartilage tissue. The cartilage ECM of the tissue comprises tightly packed proteoglycans with strong negative charges, intricately intertwined within a complex collagen network.…”

Section: Vessel-on-a-chip Models: Understanding Nanomedicine Transportmentioning

confidence: 99%

See 1 more Smart Citation

Achieving Precision Healthcare through Nanomedicine and Enhanced Model Systems

Svensson,

von Mentzer,

Stubelius

2023

ACS Mater. Au

View full text Add to dashboard Cite

The ability to customize medical choices according to an individual’s genetic makeup and biomarker patterns marks a significant advancement toward overall improved healthcare for both individuals and society at large. By transitioning from the conventional one-size-fits-all approach to tailored treatments that can account for predispositions of different patient populations, nanomedicines can be customized to target the specific molecular underpinnings of a patient’s disease, thus mitigating the risk of collateral damage. However, for these systems to reach their full potential, our understanding of how nano-based therapeutics behave within the intricate human body is necessary. Effective drug administration to the targeted organ or pathological niche is dictated by properties such as nanocarrier (NC) size, shape, and targeting abilities, where understanding how NCs change their properties when they encounter biomolecules and phenomena such as shear stress in flow remains a major challenge. This Review specifically focuses on vessel-on-a-chip technology that can provide increased understanding of NC behavior in blood and summarizes the specialized environment of the joint to showcase advanced tissue models as approaches to address translational challenges. Compared to conventional cell studies or animal models, these advanced models can integrate patient material for full customization. Combining such models with nanomedicine can contribute to making personalized medicine achievable.

show abstract

Section: Advanced Models To Explore Personalized Nanomedicinesmentioning

confidence: 99%

Section: Vessel-on-a-chip Models: Understanding Nanomedicine Transportmentioning

confidence: 99%

Achieving Precision Healthcare through Nanomedicine and Enhanced Model Systems

Svensson,

von Mentzer,

Stubelius

2023

ACS Mater. Au

View full text Add to dashboard Cite

show abstract

“…Ankle OA, for example, is often secondary to factors such as trauma, chronic ankle instability, malalignment, and arthropathies [ 5 ]. OA is a heterogeneous disease with multiple etiologies, clinical phenotypes, and molecular endotypes, which necessitates differential targeting approaches, opening pathways for the development of effective disease-modifying OA drugs (DMOADs) [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Hypoxic Conditions Modulate Chondrogenesis through the Circadian Clock: The Role of Hypoxia-Inducible Factor-1α

Juhász,

Hajdú,

Kovács

et al. 2024

Cells

View full text Add to dashboard Cite

Hypoxia-inducible factor-1 (HIF-1) is a heterodimer transcription factor composed of an alpha and a beta subunit. HIF-1α is a master regulator of cellular response to hypoxia by activating the transcription of genes that facilitate metabolic adaptation to hypoxia. Since chondrocytes in mature articular cartilage reside in a hypoxic environment, HIF-1α plays an important role in chondrogenesis and in the physiological lifecycle of articular cartilage. Accumulating evidence suggests interactions between the HIF pathways and the circadian clock. The circadian clock is an emerging regulator in both developing and mature chondrocytes. However, how circadian rhythm is established during the early steps of cartilage formation and through what signaling pathways it promotes the healthy chondrocyte phenotype is still not entirely known. This narrative review aims to deliver a concise analysis of the existing understanding of the dynamic interplay between HIF-1α and the molecular clock in chondrocytes, in states of both health and disease, while also incorporating creative interpretations. We explore diverse hypotheses regarding the intricate interactions among these pathways and propose relevant therapeutic strategies for cartilage disorders such as osteoarthritis.

show abstract

“…In 2019, there were over 500 million people with the disease [ 4 ]. The prevalence of OA is one in five among the general population and one in three among those over the age of 50 [ 3 , 5 , 6 ]. There are a variety of synovial joints that can develop OA, but the hands, knees, and hips are the most commonly affected [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

The Role of MicroRNAs in the Pathophysiology of Osteoarthritis

Szala,

Kopańska,

Trojniak

et al. 2024

IJMS

View full text Add to dashboard Cite

Worldwide, osteoarthritis (OA) is the most common cause of joint pain in older people. Many factors contribute to osteoarthritis’ development and progression, including secondary osteoarthritis’ underlying causes. It is important to note that osteoarthritis affects all four tissues: cartilage, bone, joint capsule, and articular apparatus. An increasingly prominent area of research in osteoarthritis regulation is microRNAs (miRNAs), a small, single-stranded RNA molecule that controls gene expression in eukaryotes. We aimed to assess and summarize current knowledge about the mechanisms of the action of miRNAs and their clinical significance. Osteoarthritis (OA) is affected by the interaction between miRNAs and inflammatory processes, as well as cartilage metabolism. MiRNAs also influence cartilage cell apoptosis, contributing to the degradation of the cartilage in OA. Studies have shown that miRNAs may have both an inhibitory and promoting effect on osteoporosis progression through their influence on molecular mechanisms. By identifying these regulators, targeted treatments for osteoarthritis may be developed. In addition, microRNA may also serve as a biomarker for osteoarthritis. By using these biomarkers, the disease could be detected faster, and early intervention can be instituted to prevent mobility loss and slow deterioration.

show abstract

Biomarkers for osteoarthritis: Current status and future prospects

Cited by 7 publications

References 85 publications

Achieving Precision Healthcare through Nanomedicine and Enhanced Model Systems

Achieving Precision Healthcare through Nanomedicine and Enhanced Model Systems

Hypoxic Conditions Modulate Chondrogenesis through the Circadian Clock: The Role of Hypoxia-Inducible Factor-1α

The Role of MicroRNAs in the Pathophysiology of Osteoarthritis

Contact Info

Product

Resources

About